Clinical Trial: A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07681596) titled 'A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma' on June 26.

Brief Summary: The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.

Study Start Date: July 09

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Multiple Myeloma

Intervention: BIOLOGICAL: AZD4045

Allogeneic Chimeric Antigen Receptor T cell (CAR-T) Therapy Targeting B Cell...